Clinical Roundup Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence December 19, 2025Vol.51 No.46
Clinical Roundup Drug combination kills OVCAR3 ovarian cancer cells, UNM researchers find December 19, 2025Vol.51 No.46
Clinical Roundup Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds December 19, 2025Vol.51 No.46
Drugs & Targets FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer December 19, 2025Vol.51 No.46
Drugs & Targets FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma December 19, 2025Vol.51 No.46
Drugs & Targets FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results December 19, 2025Vol.51 No.46
Drugs & Targets EC approval of Minjuvi in relapsed or refractory follicular lymphoma December 19, 2025Vol.51 No.46
Conversation with The Cancer Letter John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC December 12, 2025Vol.51 No.45By Jacquelyn Cobb and Paul Goldberg
Regulatory News FDA withdraws proposed rule for asbestos testing in talc-based cosmeticsIt’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation December 12, 2025Vol.51 No.45By Claire Marie Porter
Regulatory News ESMO publishes guidances on AI tools for clinicians, patients, and researchersSays one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.” December 12, 2025Vol.51 No.45By Sara Willa Ernst
